About Hikma Pharmaceuticals PLC (HIK)
Hikma Pharmaceuticals PLC is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in London, United Kingdom. HIK has been publicly traded since 2005, giving it 21+ years of trading history.
Hikma Pharmaceuticals PLC (HIK) has been publicly traded since 2005, making it a 21-year-old public company. It operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company is headquartered in London, United Kingdom and employs approximately 9,400 people. With a market capitalization of £2.7 billion, HIK is a mid-sized company with growth potential.
HIK trades on the London Stock Exchange and is classified as a mid-cap-cap stock with a market capitalization of approximately £2.7 billion. The company employs approximately 9,400 people worldwide.
Key Statistics
- Current Price
- £1,240.00
- Market Cap
- £2.72B
- 52-Week High
- £2,164.00
- 52-Week Low
- £1,187.00
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
HIK Investment Performance
HIK has declined 20.0% year-to-date in 2026. Over the past 5 years, a £1,000 investment in HIK would have grown to £561, representing a -43.9% total return. Since its IPO in 2005, a £1,000 investment would now be worth £4,373.
£1,000 Invested in Hikma Pharmaceuticals PLC (HIK)
How much would £1,000 invested in HIK be worth today?
What would £1,000 invested in HIK 1 year ago be worth today?
A £1,000 investment in Hikma Pharmaceuticals PLC (HIK) in 2025 would be worth £611 as of March 2026, representing a -38.9% total return.
What would £1,000 invested in HIK 3 years ago be worth today?
A £1,000 investment in Hikma Pharmaceuticals PLC (HIK) in 2023 would be worth £747 as of March 2026, representing a -25.3% total return.
What would £1,000 invested in HIK 5 years ago be worth today?
A £1,000 investment in Hikma Pharmaceuticals PLC (HIK) in 2021 would be worth £561 as of March 2026, representing a -43.9% total return.
What would £1,000 invested in HIK 10 years ago be worth today?
A £1,000 investment in Hikma Pharmaceuticals PLC (HIK) in 2016 would be worth £666 as of March 2026, representing a -33.4% total return.
What would £1,000 invested in HIK at IPO be worth today?
A £1,000 investment in Hikma Pharmaceuticals PLC (HIK) at IPO would be worth £4,373 as of March 2026, representing a +337.3% total return.
Monthly Returns Heatmap
Over the past 20+ years (244 months), Hikma Pharmaceuticals PLC (HIK) has averaged a monthly return of +0.97% with a median return of +0.32%. The stock had 131 positive months (54%) and 112 negative months (46%). The best month in HIK's history was March 2018 with a +40.3% return, while the worst was August 2022 at -24.1%. Historically, December tends to be the strongest month (averaging +4.6%), and November the weakest (-2.7%).
HIK's longest winning streak was 8 consecutive months of gains, while its longest losing streak was 9 consecutive months of losses. The best full year was 2014 with a cumulative return of +54.3%, and the worst was 2017 at -45.5%.
Annual Returns
Over 21 years of trading history, Hikma Pharmaceuticals PLC (HIK) has delivered an average annual return of +10.26% with a median return of +15.30%. The compound annual growth rate (CAGR) is +5.49%. The stock posted gains in 12 years (57%) and losses in 9 years (43%).
HIK's best year was 2014 with a +64.80% gain, while the worst was 2017 at -40.08%. The longest streak of consecutive positive years was 4, and the longest losing streak was 2 years. HIK achieved double-digit gains (10%+) in 12 years. It suffered double-digit losses in 8 years.
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | -20.00% | £1,550.00 | £1,240.00 |
| 2025 | -22.20% | £1,992.25 | £1,550.00 |
| 2024 | +11.44% | £1,787.78 | £1,992.25 |
| 2023 | +15.30% | £1,550.53 | £1,787.78 |
| 2022 | -30.04% | £2,216.38 | £1,550.53 |
| 2021 | -11.86% | £2,514.62 | £2,216.38 |
| 2020 | +26.49% | £1,987.96 | £2,514.62 |
| 2019 | +16.05% | £1,713.07 | £1,987.96 |
| 2018 | +51.35% | £1,131.86 | £1,713.07 |
| 2017 | -40.08% | £1,889.08 | £1,131.86 |
| 2016 | -17.72% | £2,295.99 | £1,889.08 |
| 2015 | +16.28% | £1,974.51 | £2,295.99 |
| 2014 | +64.80% | £1,198.15 | £1,974.51 |
| 2013 | +57.84% | £759.10 | £1,198.15 |
| 2012 | +22.76% | £618.38 | £759.10 |
| 2011 | -23.59% | £809.27 | £618.38 |
| 2010 | +59.14% | £508.54 | £809.27 |
| 2009 | +45.73% | £348.95 | £508.54 |
| 2008 | -26.04% | £471.79 | £348.95 |
| 2007 | +29.58% | £364.09 | £471.79 |
| 2006 | -9.75% | £403.45 | £364.09 |
HIK Investment Analysis: Valuation, Risk & Dividends
Key factors to consider when evaluating Hikma Pharmaceuticals PLC as an investment
Valuation
HIK currently trades at a trailing P/E ratio of 9.1, which is considered low relative to the broader market. The forward P/E of 6.7 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 141.0. The price-to-sales ratio is 0.8.
Dividends
Hikma Pharmaceuticals PLC pays a dividend to shareholders with a current yield of 5.00%. This translates to £0.62 per share annually. The payout ratio of 46% indicates sustainable dividend coverage.
Risk & Volatility
HIK has a beta of 0.65, indicating it is less volatile than the overall market. The stock's 52-week range is £1187.00 to £2164.00, and it currently trades near its 52-week low.
Analyst Ratings
Based on 11 analyst opinions, HIK has a consensus "buy" rating. The average price target of £1972.45 suggests 59.1% upside from current levels.
Frequently Asked Questions: HIK
What sector is HIK in? ▼
HIK operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. This sector includes pharmaceutical companies, biotechnology firms, medical device manufacturers, and healthcare providers.
How has HIK performed historically? ▼
Over 21 years of trading history, HIK has posted gains in 12 years (57% of the time). The best year was 2014 with a +64.8% return. Past performance does not guarantee future results.
How can I invest in HIK? ▼
You can invest in HIK through any brokerage account that offers access to the London Stock Exchange. Popular options include commission-free brokers like Fidelity, Charles Schwab, or Robinhood (US), or international brokers like Interactive Brokers. You can buy individual shares or invest through ETFs that hold HIK.
Does HIK pay dividends? ▼
Hikma Pharmaceuticals PLC pays a dividend to shareholders with a current yield of 5.00%. This translates to £0.62 per share annually. The payout ratio of 46% indicates sustainable dividend coverage.
What does Hikma Pharmaceuticals PLC do? ▼
Hikma Pharmaceuticals PLC is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in London, United Kingdom.
What sector is HIK in? ▼
HIK operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
When did HIK go public? ▼
Hikma Pharmaceuticals PLC went public in 2005, making it a 21-year-old public company as of 2026.
How much would £1,000 invested in HIK 5 years ago be worth today? ▼
A £1,000 investment in HIK five years ago would be worth approximately £561 today, representing a -43.9% return.
Does HIK pay dividends? ▼
Yes, Hikma Pharmaceuticals PLC pays a dividend with a current yield of 5.00%, which is £0.62 per share annually.
What is HIK's market cap? ▼
Hikma Pharmaceuticals PLC has a market capitalization of £2.7 billion, classifying it as a mid-cap company.
What is HIK's P/E ratio? ▼
HIK has a trailing P/E ratio of 9.1 and a forward P/E of 6.7, which measures how much investors are paying per dollar of earnings.
Is HIK a buy, hold, or sell? ▼
Based on 11 opinions, HIK has a consensus "buy" rating. The average price target is £1972.45.
Last updated: 3/14/2026